Prior to joining MediWound, Dr. Klinger was Vice President of Research and Development at Proteologics Ltd since July 2011, where she was responsible for discovery projects in the ubiquitin system, conducted in collaboration with GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd. Prior to this, Dr. Klinger served for 17 years in numerous leadership positions at Teva’s global innovative R&D division and served as Teva’s Board representative at various biotechnology companies. Dr. Klinger was a key member of the Copaxone® development team. As a project leader she led the chemistry, manufacture and control, preclinical, clinical and post-marketing R&D activities of various innovative treatments for multiple sclerosis (MS), autoimmune and neurological diseases. From 2006 to 2011, as a Senior Director at Teva, Dr. Klinger was a member of Teva’s global innovative R&D management team. From 2006 to 2008, she served as the Head of MS and Autoimmune Diseases at Teva, and led the Life Cycle Management (LCM)
Mrs. Solomon joined MediWound in November 2006.Prior to joining MediWound, she served in several financial positions in private companies. Mrs. Solomon has vast experience in accounting, budgeting and financial planning & control. Mrs. Solomon holds a B.Sc. in Business Administration from the Business Management College, Israel and a MBA from NYU Polytechnic School of Engineering, New-York.
Dr. Shoham joined MediWound in January 2013.He is a practicing board-certified Plastic and Reconstructive Surgeon with a special interest in burns, wounds and reconstructions. Dr. Shoham holds an M.D. degree from the Ben-Gurion University of the Negev and is a member of the Israeli Society of Plastic and Aesthetic Surgery, the American Burn Association, the European Burn Association and the Israeli Burn Association.